Evaluate the Clinical Equivalence of Two Naftifine HCl 1% Creams in Patients With Interdigital Tinea Pedis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01580891|
Recruitment Status : Completed
First Posted : April 19, 2012
Last Update Posted : May 6, 2014
Taro Pharmaceuticals USA
Information provided by (Responsible Party):
Taro Pharmaceuticals USA
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
The objective of this study is to evaluate the efficacy and safety of the test formulation of Naftifine HCl Cream 1% (Taro Pharmaceuticals Inc.) as compared to the already marketed formulation Naftin® (Naftifine HCl) 1% Cream (Merz Pharmaceuticals) and placebo in patients with tinea pedis and to show the superiority of the active treatments over placebo when dosed once a day for 28 days.
|Condition or disease||Intervention/treatment||Phase|
|Tinea Pedis||Drug: Naftifine HCl Cream 1% Drug: Naftin® (Naftifine HCl) Cream 1% Drug: Placebo topical cream||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||1053 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Randomized, Double-Blind, Placebo-Controlled, Multiple-Site, Parallel Design Study to Evaluate the Clinical Equivalence of Two Naftifine HCl 1% Creams in Patients With Interdigital Tinea Pedis.|
|Study Start Date :||May 2012|
|Actual Primary Completion Date :||March 2013|
|Actual Study Completion Date :||July 2013|
Resource links provided by the National Library of Medicine
MedlinePlus related topics: Athlete's Foot Tinea Infections
Drug Information available for: Naftifine hydrochloride
Experimental: Naftifine HCl Cream 1%
Naftifine HCl Cream 1% (Taro Pharmaceuticals Inc.)
Drug: Naftifine HCl Cream 1%
Naftifine HCl Cream 1% applied topically once a day for 28 days.
Active Comparator: Naftin® (Naftifine HCl) Cream 1%
Naftin® (Naftifine HCl) Cream 1% (Merz Pharmaceuticals)
Drug: Naftin® (Naftifine HCl) Cream 1%
Naftin® (Naftifine HCl) Cream 1% applied topically once a day for 28 days.
Placebo Comparator: Placebo topical cream
Placebo topical cream (Taro Pharmaceuticals Inc.)
Drug: Placebo topical cream
Placebo topical cream applied topically once a day for 28 days.
Primary Outcome Measures :
- Therapeutic Cure [ Time Frame: 42 Days ]Patients with both mycological cure and clinical cure at the final follow-up visit two weeks fter the end of treatment (Day 42) will be considered therapeutic cures.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Male or non-pregnant, non-lactating females 18 years of age or older.
- Signed informed consent form, which meets all criteria of current FDA regulations.
- If female and of child-bearing potential, have a negative urine pregnancy test at baseline visit, and prepare to abstain from sexual intercourse or use a reliable method of contraception during the study.
- A total score of at least 4 for the clinical signs and symptoms of tinea pedis for the target lesion. In addition, the most infected area must have a minimum score of at least 2 for erythema and a minimum score of at least 2 for scaling.
- A confirmed clinical diagnosis of tinea pedis with lesions localized to the interdigital spaces or predominantly interdigital, but may extend to other areas of the foot.
- The presence of tinea pedis infection, confirmed by the observation of segmented fungal hyphae during a microscopic 10% potassium hydroxide wet mount examination.
- Females who are pregnant, lactating or likely to become pregnant during the study.
- Use of antipruritics, including antihistamines within 72 hours prior to baseline visit.
- Use of topical corticosteroids, antibiotics or antifungal therapies within 2 weeks prior to baseline visit.
- Use of systemic corticosteroids, antibiotics or antifungal therapies within 1 month prior to baseline visit.
- Use of oral terbinafine or itraconazole within 2 months prior to baseline visit.
- Use of immunosuppressive medication or radiation therapy within 3 months prior to baseline visit.
- Any known hypersensitivity to Naftifine HCl, any component of the formulation or other antifungal agents.
- Confluent, diffuse moccasin-type tinea pedis of the entire plantar surface.
- Significant history or current evidence of chronic infectious disease, system disorder, organ disorder, or other medical condition that would place the patient at undue risk by participation or could jeopardize the integrity of the study evaluations.
- Evidence of any concurrent dermatophytic infection of the toe nails or dermatological condition of the foot that may interfere with the evaluation of tinea pedis.
- Patients with a past history of tinea pedis infections with a lack of response to antifungal therapy.
- Patients who would be non-compliant with the requirements of the study protocol.
- Participation in a research study within 30 days prior to baseline visit.
- Employees or family members of employees of the research center or investigator.
- Previous participation in this study.
No Contacts or Locations Provided
|Responsible Party:||Taro Pharmaceuticals USA|
|Other Study ID Numbers:||
|First Posted:||April 19, 2012 Key Record Dates|
|Last Update Posted:||May 6, 2014|
|Last Verified:||May 2014|
Keywords provided by Taro Pharmaceuticals USA:
Naftifine HCl Cream 1%
Naftin® (Naftifine HCl) Cream 1%
Efficacy and safety
Additional relevant MeSH terms:
Bacterial Infections and Mycoses
Skin Diseases, Infectious